At Synnovis we're helping to improve care for breast cancer patients by introducing a liquid biopsy technique, called circulating tumour DNA (ctDNA) testing, to monitor and detect tumour progression. Healthcare professionals can provide patients with accurate data and treatment based on information collected from a simple blood sample, potentially eliminating the need for invasive biopsies. Liquid biopsy technology has the potential to: ➡ reduce or avoid invasive biopsies ➡ identify other tumours in the body, which could otherwise be missed ➡ achieve quicker results for patients ➡ reduce the need for follow-up investigations. Learn more from Synnovis geneticists Persephone du Parcq, Gareth Gerrard and Deborah Ruddy about how scientific excellence and patient centricity are at the heart of this cutting-edge service. SYNLAB UK & Ireland #BreastCancerAwareness #PinkOctober #liquidbiopsy #oncology
In the UK, Synnovis is acting ahead of the wave to improve patient care for breast cancer by introducing a liquid biopsy technique, called circulating tumour DNA (ctDNA) testing, to monitor and detect tumour progression. Healthcare professionals can provide patients with accurate data and treatment based on information collected from a simple blood sample, potentially eliminating the need for invasive biopsies. Liquid biopsy technology has the potential to: ➡ reduce or avoid invasive biopsies ➡ identify other tumours in the body, which could otherwise be missed ➡ achieve quicker results for patients ➡ reduce the need for follow-up investigations. Learn more from Synnovis geneticists Persephone du Parcq, Gareth Gerrard and Deborah Ruddy on how scientific excellence and patient centricity are at the heart of this cutting-edge service. Synnovis SYNLAB UK & Ireland #BreastCancerAwareness #PinkOctober #liquidbiopsy #oncology